Search
Vorapaxar
go.drugbank.com/drugs/DB09030ApprovedBy inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. … Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMiltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalMiltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and ...
Categories: P-glycoprotein substratesIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIbrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibruti...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesOlaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigationalOlaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in c...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsUmeclidinium
go.drugbank.com/drugs/DB09076ApprovedInvestigational[A7719] By blocking the M3 muscarinic receptor, umeclidinium inhibits the binding of acetylcholine and thereby opens up the airways by preventing bronchoconstriction.
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalNintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United Sta...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalIvabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBenzydamine
go.drugbank.com/drugs/DB09084ApprovedInvestigationalBenzydamine (also known as Tantum Verde or Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties. It is used topically for pain reli...
Products: TANTUM VERDE PElvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 InducersStiripentol
go.drugbank.com/drugs/DB09118ApprovedInvestigationalStiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs. The clinical development and marketing of stiripentol were first delayed due to the drug's...
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors